Moberg Pharma has previously had several successful treatments for nail fungus on the market. Now it is on the way with its latest product, MOB-015. The company recently received market approval in Sweden and Ireland and is currently conducting a rights issue of approximately SEK 100 million to continue development and market preparations. In connection with this, BioStock invited CEO Anna Ljung to find out more about the development and how the issue proceeds will be used.
Watch the interview with Moberg Pharma vd Anna Ljung hereinafter.
This material has been prepared for marketing purposes and is not and shall not be considered to constitute a prospectus under applicable laws and regulations. The full terms and conditions of the rights issue and further information about the company have been set out in a prospectus which was published and published on mobergpharma.se on August 14, 2023.
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
Unlock our premium content: Become a subscriber!
Create Account
